IDH1-mutated malignancies
Clinical trials for IDH1-mutated malignancies explained in plain language.
Never miss a new study
Get alerted when new IDH1-mutated malignancies trials appear
Sign up with your email to follow new studies for IDH1-mutated malignancies, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets tough blood cancers
Disease control Recruiting nowThis phase 2 trial tests a drug called olutasidenib combined with other targeted therapies for people with relapsed or hard-to-treat blood cancers that have a specific IDH1 mutation plus other signaling mutations. The study aims to see how safe and tolerable these drug combinatio…
Matched conditions: IDH1-MUTATED MALIGNANCIES
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New study explores ivosidenib dosing for cancer patients with organ issues
Knowledge-focused Recruiting nowThis early-stage study is testing the safety and how the body handles ivosidenib in 30 adults with IDH1-mutated cancers who also have liver or kidney problems. Participants take a daily ivosidenib pill and are monitored closely with blood tests and check-ups. The goal is to learn…
Matched conditions: IDH1-MUTATED MALIGNANCIES
Phase 1 • Sponsor: Servier Bio-Innovation LLC • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC